Online inquiry

IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8669MR)

This product GTTS-WQ8669MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD38 gene. The antibody can be applied in Multiple myeloma (MM), AL amyloidosis research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001775.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 952
UniProt ID P28907
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ8669MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14729MR IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SGN-19A
GTTS-WQ12332MR IVTScrip™ mRNA-Anti-TIGIT, MTIG-7192-A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MTIG-7192-A
GTTS-WQ9929MR IVTScrip™ mRNA-Anti-EPHA3, KB-004(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA KB-004
GTTS-WQ983MR IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABBV-368
GTTS-WQ2243MR IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ALX-0171
GTTS-WQ9087MR IVTScrip™ mRNA-Anti-CD3E&PMEL, IMCgp100(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMCgp100
GTTS-WQ4589MR IVTScrip™ mRNA-Anti-CD40LG, BMS-986004(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BMS-986004
GTTS-WQ13823MR IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN-10987
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW